Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
|
|
- Marilynn Hancock
- 5 years ago
- Views:
Transcription
1 Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
2 OUTLINE Molecular Rationale for the use of SSAs in NETs Antihormonal effect Antiproliferative effect Clinical data of SSAs activity in NETs SSAs in combination with other MTTs
3 NEUROENDOCRINE NEOPLASMS: WHY SSA? SECRETION PROLIFERATION Hormones Amines (eg, serotonin) Tachykinins Granins (eg, CgA) Growth factors (eg, IGF-1) NEN, Neuroendocrine neoplasms, SSA, somatostatin analogs
4 CELL BIOLOGICAL MECHANISMS OF ACTION OF SSA hormone secretion auto-/paracrine secretion of growth factors receptor phosphorylation proliferation angiogenesis signal transduction apoptosis cell cycle arrest (G1) Lamberts SW, et al. N Engl J Med. 1996
5 SOMATOSTATIN RECEPTOR SUBTYPE-BINDING AFINITY OF SSA Grozinsky-Glasberg S, et al. Endocr Relat Cancer 2008
6 MAJORITY OF PATIENTS ACHIEVE COMPLETE OR PARTIAL CONTROL OF SYMPTOMS ON SSA Symptomatic response 100 (74.2) (71) (77.3) (75) (63.0) (63) (67.5) (63) % of response Flushing n=53 Diarrhea n=49 25% 57% 74% 89% >50% Improvement Complete response 0 OCT OCT LAR LAN LAN SR+AG Studies n=11 n=7 n=1 n=7 Patients n=261 n=122 n=30 n=185 5-HIAA n=57 68% 5% Patients with improvement (%) Octreotide Lanreotide
7 SSA RECEPTORS DOWNSTREAM CASCADE Effect of SSA on phosphorilation of different residues of mtor pathway Grozinsky-Glasberg S, et al. Endocr Relat Cancer 2008
8 ANTIPROLIFERATIVE EFFECT OF SSA IN PATIENTS WITHOUT DOCUMENTED PD OR ~5% SD 60-70% Toumpanakis C, et al. Semin Oncol 2013
9 ANTIPROLIFERATIVE EFFECT OF SSA IN PATIENTS WITH DOCUMENTED PD OR ~5% SD 40-45% Toumpanakis C, et al. Semin Oncol 2013
10 PROSPECTIVE CLINICAL TRIAL IN PROGRESSIVE NETS: SPANISH STUDY (TTD) NET ORIGIN (n=30) n (%) Pancreas 8 (26,7) Gastric 1 (3,3) Duodenum 1 (3,3) Ileum 6 (20,0) Jejunum 3 (10) Caecum 2 (6,7) Right colon 1 (3,3) Lung 4 (13,3) Unknown 4 (13,3) mpfs 12,9 months (IC 95%: 7,9-16,5) Treatment LANREOTIDE AUTOGEL 120 mg every 28 days Martin-Richard M, et al. BMC Cancer 2013
11 PROSPECTIVE CLINICAL TRIAL IN PROGRESSIVE NETS: SPANISH STUDY (TTD) Partial Response: 4% Stabilization: 89% Progression: 7% Martin-Richard M, et al. BMC Cancer 2013
12 PROSPECTIVE TRIALS OF SSA IN SMALL INTESTINE NETS Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine MIDgut tumors: A Report From the PROMID Study Group Phase III, randomized, double-blind, placebo-controlled 18 centers in Germany ( ) Patients with midgut NETs Treatment-naïve Histologically confirmed Locally inoperable or metastatic Well-differentiated Measurable (CT/MRI) Functioning or non-functioning RANDOMIZATION (1:1) Octreotide LAR 30 mg im every 28 days Placebo im every 28 days Treatment until CT/MRI documented tumor progression or death Rinke A, et al. J Clin Oncol. 2009
13 PROMID STUDY: GRADE 1 AND LOW LIVER INVOLVEMENT SMALL INTESTINE NETS (81/85 Ki67 <2%) Carcinoid syndr. Hepatic tumor load Per Protocol Analysis Octreotide LAR Placebo N Median PFS, mo Median PFS, mo HR [95% CI] Carcinoid syndrome [ ] Inactive tumor [ ] Liver involvement 0% [ ] Liver involvement 0%-10% [ ] Liver involvement 10%-50% [ ] Liver involvement >50% [ ] Patients, proportion Placebo, 40 events; median, 6.0 months Octreotide LAR, 26 events; median, 14.3 months Rinke A, et al. J Clin Oncol. 2009
14 THE PROMID STUDY: OCTREOTIDE LAR IN MIDGUT NETS WHAT DID WE LEARN? Lessons Octreotide LAR shows antitumor effect in: Midgut tumors Low hepatic tumor burden (<10%) Grade 1 tumors Limitations The efficacy of Octreotide LAR is uncertain in: Non-midgut tumors Higher liver tumor burden (<10%) Grade 2 tumors Non-Progressive disease
15 THE CLARINET STUDY A randomized double-blind placebo-controlled phase III study of Lanreotide Antiproliferative Response In enteropancreatic NET n = Patients with GEP-NET Histologically confirmed Measurable (CT / MRI) Grade 1 / grade 2 well / mod differentiated (Ki67 <10%) [WHO 2010 classification] Locally inoperable or metastatic Nonfunctioning only R A N D O M I Z A T I O N ( 1 : 1 ) Lanreotide Autogel 120 mg sc every 28 days Placebo every 28 days Treatment continued until tumor progression or death we e k s C l i n i c a l T ri a l s. g o v N C T Eu d ra C T Primary endpoint: PFS Secondary endpoints: Adverse events, pharmacokinetics, quality of life, CgA serum levels Caplin ME, et al. N Engl J Med. 2014
16 CLARINET: BASELINE CHARACTERISTICS Lanreotide (n=101) Placebo (n=103) Men, n (%) 53 (52) 54 (52) Age in years, mean (SD) 63.3 (9.8) 62.2 (11.1) NET origin, n (%) Pancreas Midgut Hindgut Unknown/other 42 (42) 33 (33) 11 (11) 15 (15) 49 (48) 40 (39) 3 (3) 11 (11) Tumour progression, n (%) 4 (4) 5 (5) Prior treatment, n (%) 16 (16) 16 (16) Tumour grade, n (%)* 1 (Ki-67: 0 2%) 2 (Ki-67: 3 10%) Unknown Hepatic tumour volume, n (%) 0% >0 10% >10 25% >25 50% >50% 69 (68) 32 (32) 0 16 (16) 33 (33) 13 (13) 23 (23) 16 (16) 72 (70) 29 (28) 2 (2) 18 (17) 40 (39) 17 (17) 12 (12) 16 (16) Chromogranin A, n (%) 1 ULN 1 2 ULN >2 ULN 33 (33) 25 (25) 41 (41) 34 (33) 18 (17) 48 (47) *Ki-67 Unknown thresholds as per World Health Organization (WHO) 2010 classification with values 2 (2) >2 10% assigned to grade 2. 3 (3) Caplin ME, et al. N Engl J Med. 2014
17 CLARINET: LANREOTIDE PROLONG PFS IN ENTEROPANCREATIC NET Patients Alive and With No Progression, % PFS (intention to treat population) Lanreotide Autogel 120 mg 32 events / 101 patients median, not reached Placebo 60 events / 103 patients median, 18.0 months [95% CI: 12.1, 24.0] No at risk: Time, months Lanreotide Autogel vs Placebo P =.0002 HR = 0.47 [95% CI: 0.30, 0.73] % 22% Caplin ME, et al. N Engl J Med. 2014
18 CLARINET: LANREOTIDE PROLONG PFS IN ENTEROPANCREATIC NET PFS in midgut vs pancreatic NET Patients Alive and With No Progression, % Lan r eot i de A u t ogel 120 m g 8 e v e n t s / 3 3 p a t i e n t s m e d i a n, n o t r e a ch e d Mi d g u t NE T s ( n = 7 3 ) La nr e ot i de Au t o g e l vs p l aceb o P = HR = [ 9 5 % C I : , ] P l a ce b o 2 1 e v e n t s / 4 0 p a t i e n t s m e d i a n, m o n t h s [ 9 5 % C I : , N C ] Ti m e, m o nt hs Lan r eot i de A u t ogel 120 m g 1 8 e v e n t s / 4 2 p a t i e n t s m e d i a n, n o t r e a ch e d pn E T s (n = 9 1 ) La nr e ot i de Au t o g e l vs p l aceb o P = HR = [ 9 5 % C I : , ] P l a ce b o 3 1 e v e n t s / 4 9 p a t i e n t s m e d i a n, m o n t h s [ 9 5 % C I : 9. 4, ] Ti m e, m o nt hs Caplin ME, et al. N Engl J Med. 2014
19 CLARINET: LANREOTIDE PROLONG PFS IN ENTEROPANCREATIC NET PFS in grade 1 vs grade 2 (Ki-67<10%) NET Patients Alive and With No Progression, % Lan r eot i de A u t ogel 120 m g 1 9 e v e n t s / 6 9 p a t i e n t s m e d i a n, n o t r e a ch e d Grade 1 tumors (n= 141) Grade 2 tumors (n= 61) La nr e ot i de Au t o g e l vs p l aceb o La nr e ot i de Au t o g e l vs p l aceb o P = HR = [ 95 % C I : 0. 25, ] 100 P = HR = [ 95 % C I : 0. 22, ] Ti m e, m o n t h s Lan r eot i de A u t ogel 120 m g 1 3 e v e n t s / 3 2 p a t i e n t s m e d i a n, n o t r e a ch e d 20 P l a ce b o P l a ce b o 40 e v e n t s / 72 p a t i e n t s e v e n t s / 29 p a t i e n t s m e d i a n, m o n t h s [ 95 % C I : 12. 7, ] m e d i a n, m o n t h s [ 95 % C I : 9. 0, ] Ti m e, m o n t h s P va l u e d e r i ve d f r o m l o g - r a n k t e st ; H R d e r i v e d f r o m C o x p r o p o r t i o n a l h a z a r d s m o d e l Caplin ME, et al. N Engl J Med. 2014
20 CLARINET: LANREOTIDE PROLONG PFS IN ENTEROPANCREATIC NET PFS low vs high hepatic tumor load Patients Alive and With No Progression, % Lan r eot i de A u t ogel 120 m g 1 4 e v e n t s / 6 2 p a t i e n t s m e d i a n, n o t r e a ch e d Tumor load 25% (n=137) La nr e ot i de Au t o g e l vs p l aceb o P = HR= [ 95 % C I : 0. 18, ] 20 P l a ce b o 41 e v e n t s / 75 p a t i e n t s 10 m e d i a n, m o n t h s [ 95 % C I : 17. 6, ] Ti m e, m o n t h s Tu m o r l o a d > 2 5 % ( n = 6 7 ) La nr e ot i de Au t o g e l vs p l aceb o P = HR= [ 9 5 % C I : , ] Lan r eot i de A u t ogel 120 m g 1 8 e v e n t s / 3 9 p a t i e n t s m e d i a n, m o n t h s [ 9 5 % C I : 9. 3, N C ] P l a ce b o 1 9 e v e n t s / 2 8 p a t i e n t s m e d i a n, 9. 4 m o n t h s [ 9 5 % C I : 6. 3, ] Ti m e, m o n t h s P va l u e d e r i ve d f r o m l o g - r a n k t e st ; H R d e r i v e d f r o m C o x p r o p o r t i o n a l h a z a r d s m o d e l ; N C, n o t ca l cu l a b l e Caplin ME, et al. N Engl J Med. 2014
21 CLARINET: LANREOTIDE IS WELL TOLERATED AND EFFECTIVE WITHOUT COMPROMISING QUALITY OF LIFE Adverse events (safety population) Lanreotide shows a good safety profile consistent with other SSA studies Diarrhea most prominent adverse events Quality of life is unchanged (EORTC-QLQ C30) Caplin ME, et al. N Engl J Med. 2014
22 CLARINET OPEN LABEL EXTENSION STUDY PFS (40 patients with stable disease [SD] continuing on lanreotide: LAN-LAN group) Patients Alive and With No Progression, % Core study Central radiological assessment Placebo 61 events/103 patients median, 18.0 months [95% CI: 12.1, 24.0] Extension study Local radiological assessment Lanreotide Autogel 45 events/101 patients (core: 32 events/101 patients; OLE: 13 events/40 patients) median, 32.8 months [95% CI: 30.9, 68.0] 40 patients with SD while receiving lanreotide in the core study continued into the Open Label Extension study Time From Randomization in Core Study, months Caplin M, et al. J Clin Oncol. 2014;32(5s): Abstract 4107
23 CLARINET STUDY: LANREOTIDE IS EFFECTIVE IN PROGRESSIVE ENTEROPANCREATIC NET Time to progression (TTP) in placebo patients with progressive disease (PD) (32 patients with PD starting on lanreotide: PBO-LAN group) Patients Alive and With No Progression, % Switched to lanreotide Autogel 17 events/32 patients median, 14.0 months [95% CI: 10.1, NC] Time From Centrally Assessed PD in Core Study, months Caplin M, et al. J Clin Oncol. 2014;32(5s): Abstract 4107
24 CONCLUSIONS CLARINET Lanreotide substantially prolongs PFS in metastatic well / moderately differentiated enteropancreatic NETs Median PFS with lanreotide not reached vs 18 months with placebo (P =.0002) 53% risk reduction for progression / death Antiproliferative effect was observed In patients with grade 1 and grade 2 tumors (Ki67 <10%) In patients with low and high hepatic tumor load In patients with primary tumors in small intestine and pancreas In patients with progressive disease (Open Label Extension Study) Very good tolerability consistent with previous studies Data supports important role in treatment algorithm for GEP-NETs Caplin ME, et al. N Engl J Med Caplin M, et al. J Clin Oncol. 2014;32(5s): Abstract 4107
25 BLOCKING DIFFERENT PATHWAYS IN NETS VEGFR 1 3, PDGFR, KIT, RET SSR 1 5 Ca ++ K + SSA C-SRC Sunitinib Phospholipase C RAS PI3K Adenylate Cyclase STAT JAK-2 BRAF AKT PTEN MAPK mtor Everolimus Hormonal secretion Angiogenesis Proliferation Immune response Capdevila J, et al. Ann Oncol 2011
26 EVIDENCE OF SSA-MMT COMBINATIONS 27% concomitant SSAs 40% concomitant SSAs Raymond E, et al. N Engl J Med 2011; Yao JC, et al. N Engl J Med 2011; Pavel et al, Lancet 2011
27 MECHANISM OF RESISTANCE TO MTOR INHIBITION IGFR-1 Feedback activation of AKT following mtor inhibition by rapalogs IRS PI3K AKT PTEN PDK1 pakt-s473 staining PIP3 Tumor sample of a patient on treatment with everolimus pre-therapy on-therapy Tuberin Rheb TORC1 S6K S6 4EBP1 Modified from Di Cosimo S, et al. ASCO 2010 Tabernero J et al., J Clin Oncol 2008
28 MECHANISM OF RESISTANCE TO MTOR INHIBITION IGFR-1 Feedback activation of AKT following mtor inhibition by rapalogs IRS PI3K PTEN PDK1 AKT pakt-s473 staining PIP3 Tumor sample of a patient on treatment with everolimus pre-therapy on-therapy Tuberin Rheb TORC1 S6K S6 4EBP1 Modified from Di Cosimo S, et al. ASCO 2010 Tabernero J et al., J Clin Oncol 2008
29 MECHANISM OF RESISTANCE TO MTOR INHIBITION IGFR-1 IRS Feedback activation of AKT following mtor inhibition by rapalog PI3K AKT PTEN PDK1 pakt-s473 staining PIP3 Tumor sample of a patient on treatment with everolimus pre-therapy on-therapy Tuberin Co-treatment with IGFR1 inhibitor prevents feedback activation of AKT by mtor inhibition in preclinical models Rheb TORC1 S6K S6 4EBP1 Modified from Di Cosimo S, et al. ASCO 2010 Tabernero J et al., J Clin Oncol 2008 Di Cosimo S, et al. J Clin Oncol 2007
30 RETROSPECTIVE STUDY OF LANREOTIDE PLUS MTT IN SPANISH PATIENTS WITH NET Study identified 133 patients with NET from 35 Spanish medical oncology departments N=64 (48%) had pancreatic NET Characteristics Patients (N=133) Male/Female, n (%) 70 (52.6)/63 (47.4) Median age, years (range) 59.4 (16 83) ECOG PS, n (%) 0/1 45 (33.8)/65 (48.9) 2/3 22 (16.5)/1 (0.8) Location of primary tumour Foregut 85 (64.0) Midgut 30 (22.6) Hindgut 6 (4.6) Unknown 14 (10.5) Tumour functionality, n (%) Nonfunctioning/Functioning 92 (69.2)/41 (30.8) Capdevila J, et al. ESMO 2012
31 PROGRESSION-FREE SURVIVAL Capdevila J, et al. ESMO 2012
32 SEVERAL CLINICAL TRIALS IN NETS EXPLORING SSA IN COMBINATION WITH MMT Randomized Phase III study (SWOG0518) Octreotide + IFN vs Octreotide + Bevacizumab Randomized Phase II study (SUNLAND) Lanreotide +/- Sunitinib Randomized Phase II study (COOPERATE-II) Everolimus +/- Pasireotide Randomized Phase II study (GETNE1107) Octreotide +/- Axitinib
33 SEVERAL CLINICAL TRIALS IN NETS EXPLORING SSA IN COMBINATION WITH MMT Non-Randomized Phase II study (NCT ) Aflibercept + Octreotide Non-Randomized Phase II study (NCT ) Bevacizumab + Pertuzumab + Octreotide Non-Randomized Phase I study (NCT ) Cixutumumab + Everolimus + Octreotide Non-Randomized Phase II study (NCT ) Lanreotide + Temozolomide
34 TAKE-HOME MESSAGES SSA have become the cornerstone of the treatment of symptomatic advanced NETs There is a strong molecular rationale for an action of SSA as antiproliferative agents The CLARINET study has clearly demonstrated efficacy in tumor growth control of enteropancreatic NETs Combination of SSA with other MTT is of medical interest; Need to be confirmed by ongoing studies.
35 Muchas gracias por vuestra atención
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationOctreotide LAR in neuroendocrine tumours a summary of the experience
Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie
More informationGEP NET: algoritmo terapeutico. Dottor Nicola Fazio
GEP NET: algoritmo terapeutico Dottor Nicola Fazio Basi per il trattamento Caratteristiche del paziente Caratteristiche del tumore P.S., sindrome, comorbidità Differenziazione, Ki-67 Imaging morfologico
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationLe target therapy nei Tumori Neuroendocrini
Le target therapy nei Tumori Neuroendocrini Take home messages Franco Grimaldi SOC Endocrinologia e Malattie del Metabolismo Nutrizione Clinica Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationThe Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review
Gastrointestinal Cancer The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review MICHAEL MICHAEL, a ROCIO GARCIA-CARBONERO, b MATTHIAS M. WEBER, c CATHERINE
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationOngoing and future clinical investigation in GEP NENs
ESMO PRECEPTORSHIP PROGRAMME Multidisciplinary management, standards of care and future perspectives Lugano, Switzerland 13-14 April 2018 CHAIR: Nicola Fazio, Italy George Pentheroudakis, Greece Ongoing
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationSystematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors
At the Cutting Edge Received: February 29, 2016 Accepted: April 12, 2016 Published online: April 16, 2016 Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors Adrian Lee
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationTumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016
1 Tumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016 Philippe RUSZNIEWSKI ENETS Centre of Excellence, Beaujon Hospital, Clichy, France
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More information*Bert Bakker was an employee of Novartis Pharmaceuticals Corporation until June 06, 2014.
Page 1 of 20 Accepted Preprint first posted on 15 September 2015 as Manuscript ERC-15-0314 1 2 Efficacy of Octreotide LAR in Neuroendocrine Tumors: RADIANT-2 Placebo Arm Post Hoc Analysis 3 4 Authors:
More informationTUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca
TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different
More informationNICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationNew Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer
New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationDevelopment of New Treatment Modalities Oncolytic Viruses and Nanotechnique
Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More informationAn Immunotherapy Clinical Trial for NETs
An Immunotherapy Clinical Trial for NETs Pamela L. Kunz, MD Assistant Professor of Medicine / Oncology Stanford Cancer InsEtute March 1, 2015 Outline Clinical trial basics What have we learned from recent
More informationIART Cremona,
IART Cremona, 06-06-2018 Quale spazio per la terapia biologica? Nicola Fazio, M.D., Ph. D. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology Milan, Italy
More informationCollaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors
Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationStrategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova
Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine
More informationHot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ
Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid
More informationCase Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors
Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More informationI nuovi farmaci: associazione o superamento del trattamento con analoghi
Milano, 20 giugno 2008 I NETs: a che punto siamo? I nuovi farmaci: associazione o superamento del trattamento con analoghi Nicola Fazio NET: possible targets for novel drugs Angiogenesis VEGF, EGF, IGF,
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationGuideline A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours S. Singh, D. Sivajohanathan, T.
More informationManagement of Neuroendocrine Tumors
Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of
More informationEverolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors
CHEST Original Research Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 Study LUNG
More informationMedical treatment non-pancreatic NETs
Medical treatment non-pancreatic NETs Prof Juan Valle Professor and Honorary Consultant Institute of Cancer Sciences University of Manchester The Christie ENETS Centre of Excellence ESMO Preceptorship
More informationNEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary)
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationNET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia
NET del pancreas ben differenziato: la terapia oncologica Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia Systemic treatment op:ons Somatosta:n analogues Interpheron
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationTreatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece
Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm
More informationAn Overview of NETS. Richard R.P. Warner M.D
An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationTargeting mtor pathway in ER+/Her2- breast cancers. Fabrice ANDRE Gustave Roussy
Targeting mtor pathway in ER+/Her2- breast cancers Fabrice ANDRE Gustave Roussy Outline mtor pathway Clinical development of rapalogs in breast cancer Moving beyond rapalogs mtor pathway LKB1 Ras-raf-
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationNeuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC
Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
The new england journal of medicine original article Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Martyn E. Caplin, D.M., Marianne Pavel, M.D., Jarosław B. Ć wikła, M.D., Ph.D., Alexandria
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationNeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction
NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic
More informationAdvanced typical and atypical carcinoid tumours of the lung: management recommendations
REVIEW ARTICLE Advanced typical and atypical carcinoid tumours of the lung: management recommendations B. Melosky md* ABSTRACT Background Neuroendocrine tumours (nets) are classified by site of origin,
More informationSIRT in the Management of Metastatic Neuroendocrine Tumors
SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2016 Current Concepts in the Management of GEP-NETs: A Case Study Compendium Discussants Renuka Iyer, MD Associate Professor
More informationPrognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.
Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic
More informationUpdates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010
HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationReview Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Hindawi International Journal of Surgical Oncology Volume 2017, Article ID 6424812, 14 pages https://doi.org/10.1155/2017/6424812 Review Article Management Options for Advanced Low or Intermediate Grade
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2017 Recent Advances in the Management of Gastroenteropancreatic Neuroendocrine Tumors: Insights From the 2017 ASCO Gastrointestinal
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationInmunoterapia en el carcinoma de Células de Merkel. Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona
Inmunoterapia en el carcinoma de Células de Merkel Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Epidemiology Merkel cell carcinoma is an uncommon neuroendocrine carcinoma that mostly arises
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationNeuroendocrine Tumors
Carcinoid tumours: origin Neuroendocrine Tumors THE A, B,C s Bronchopulmonary system Other 8% 28% Carcinoid site Digestive system 64% 2.3 28 28.5 Other Colon and rectum Small intestine Colon, except appendix
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationPancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case
Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,
More informationTumor markers. Chromogranin A. Analyte Information
Tumor markers Chromogranin A Analyte Information -1-2018-04-22 Chromogranin A Introduction Chromogranin A (CgA) is a 439-amino acid protein with a molecular weight of 48 to 60 kda, depending on glycosylation
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationGrade 2 Ileum NET with liver and bone metastasis
Grade 2 Ileum NET with liver and bone metastasis BERNARDO MARQUES ENDOCRINOLOGY DEPARTMENT PORTUGUESE INSTITUTE OF ONCOLOGY - COIMBRA April 2018, Lugano, Switzerland JPB, male, 67 years old April 2015
More informationI have no financial conflicts to disclose.
I have no financial conflicts to disclose. A Tribute to Dr. Charles Moertel: Father of chemotherapy for GI cancers (NCCTG) Mayo Clinic 1954-1994 Cancer center director 1975-86 Pioneer in cancer clinical
More informationComprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases
Case Report Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases Wei Wang 1,2,3 *, Sharvesh Raj Seeruttun 1,2,3 *, Cheng Fang 1,2,3, Zhiwei Zhou 1,2,3
More informationPANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION:
PANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION: CONTACT WEBEX TECHNICAL SUPPORT DIRECTLY AT: US TOLL FREE: 1-866-779-3239 TOLL ONLY: 1-408-435-7088
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More information